Dabigatran, marketed under the brand name Pradaxa, is an oral anticoagulant developed by Boehringer Ingelheim. Approved by the FDA in 2010, Pradaxa is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). Unlike traditional blood thinners, Dabigatran directly inhibits thrombin, a key enzyme in the blood clotting process. This direct action helps prevent clot formation and reduces the risk of dangerous blood clots. Available in capsule form, Pradaxa is typically taken twice daily. Patients should adhere to their prescribed dosage and consult their healthcare provider regularly to manage any potential side effects or interactions with other medications.
